Industryweek 5824 Astrazeneca

AstraZeneca Buys Cancer Drug Firm Amplimmune

Aug. 27, 2013
Under the deal, MedImmune will acquire 100% of Amplimmune's shares for an initial price of $225 million, with another $275 million deferrred until it reaches key drug development milestones.

LONDON - AstraZeneca (IW 1000/157) said on Tuesday that it has agreed to buy U.S.-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceuticals group seeks to bolster its flagging pipeline of new products.

Under the deal, MedImmune will acquire 100% of Amplimmune's shares for an initial price of $225 million, with another $275 million deferrred until it reaches key drug development milestones.

"AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately held, Maryland, U.S.-based biologics company focused on developing novel therapeutics in cancer immunology," a statement said.

"MedImmune's focus on harnessing the power of the patient's own immune system to fight cancer will be complemented by Amplimmune's innovative work in this area," said Bahija Jallal, executive vice president of MedImmune.

"It will allow us to strengthen our arsenal of potential cancer therapies.

"We are excited to be working with the Amplimmune team to help find new treatments to address areas of unmet medical need."

Over the weekend, meanwhile, the world's top biotech firm Amgen struck a deal to buy Onyx Pharmaceuticals for $10.4 billion, joining a trend toward consolidation in the drug making industry.

The deal will allow Amgen (IW 500/71) to get its hands on Kyprolis, a promising treatment for blood cancer developed by Onyx and approved by U.S. authorities in 2012.

Amplimmune is AstraZeneca's latest acquisition under new chief executive Pascal Soriot, who joined in October last year.

The London-listed group purchased U.S. firm Pearl Therapeutics in June for up to $1.15 billion.

Copyright Agence France-Presse, 2013

Popular Sponsored Recommendations

Navigating Disruption: A Leader’s Guide to Strategy Under Uncertainty

Nov. 1, 2023
AI, sustainability, digital--industrials are facing disruptive forces that are redefining what it takes to win. What got your company where it is today won’t get you where you...

Food and Beverage 2024 Trends and Outlook for North America

Oct. 29, 2023
Ready to hear what 200 of your peers said are the top challenges and opportunities in 2024? Don’t fall behind. Uncover actionable insights to better prepare for 2024 in this whitepaper...

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

Beware Extreme Software

Sept. 24, 2023
As a manufacturer, you understand the importance of staying ahead of the curve and being proactive in your approach to technology. With the rapid pace of change in the industry...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!